Designer Aspirin Fights Cancer

Early experiments show that a hybrid form of the common pain reliever can effectively inhibit the growth of many tumor types.

By | March 5, 2012

Wikimedia Commons, Chaval Brasil

WIKIMEDIA COMMONS, CHAVAL BRASIL

Researchers in New York claim that new type of aspirins can slow the growth of colon, pancreas, breast, lung, and prostate cancers, as well as some types of leukemia. Scientists at the City University of New York Medical School created four new forms of aspirin that release both nitric oxide (NO) and hydrogen sulfide (H2S). They report the anti-cancer properties of these so-called NOSH-Aspirins in a paper published online in ACS Medicinal Chemistry Letters

Though regular aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have shown promise in curtailing tumor growth by knocking back inflammation, they come with nasty side effects such as the risks of gastrointestinal and brain bleeding and liver toxicity. The NOSH-Aspirins tested, on the other hand, did not seem to damage surrounding cells. Plus, one the new aspirins tested appeared to be more than 100,000 times more effective against cancer than normal aspirin.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Thousands of Mutations Accumulate in the Human Brain Over a Lifetime
  2. Can Young Stem Cells Make Older People Stronger?
  3. Two Dozen House Republicans Do an About-Face on Tuition Tax
  4. Insects’ Neural Learning and Memory Center Discovered in Crustaceans